Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 108, Issue 1, Pages 18-37Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1038/ajg.2012.373
Keywords
-
Categories
Funding
- National Institutes of Health [PO1 DK68055-04, DK67071, 1 U01 DK073975-06, U01 DK074007]
- Shire (prucalopride)
- Theravance (velusetrag)
- Rhythm [RM-131]
- Tranzyme [TZP-101, TZP-102]
- SmartPill
- Tranzyme
- GSK
- Evoke
- Rhythm
- Salix Pharmaceuticals
Ask authors/readers for more resources
This guideline presents recommendations for the evaluation and management of patients with gastroparesis. Gastroparesis is identified in clinical practice through the recognition of the clinical symptoms and documentation of delayed gastric emptying. Symptoms from gastroparesis include nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain. Management of gastroparesis should include assessment and correction of nutritional state, relief of symptoms, improvement of gastric emptying and, in diabetics, glycemic control. Patient nutritional state should be managed by oral dietary modifications. If oral intake is not adequate, then enteral nutrition via jejunostomy tube needs to be considered. Parenteral nutrition is rarely required when hydration and nutritional state cannot be maintained. Medical treatment entails use of prokinetic and antiemetic therapies. Current approved treatment options, including metoclopramide and gastric electrical stimulation (GES, approved on a humanitarian device exemption), do not adequately address clinical need. Antiemetics have not been specifically tested in gastroparesis, but they may relieve nausea and vomiting. Other medications aimed at symptom relief include unapproved medications or off-label indications, and include domperidone, erythromycin (primarily over a short term), and centrally acting antidepressants used as symptom modulators. GES may relieve symptoms, including weekly vomiting frequency, and the need for nutritional supplementation, based on open-label studies. Second-line approaches include venting gastrostomy or feeding jejunostomy; intrapyloric botulinum toxin injection was not effective in randomized controlled trials. Most of these treatments are based on open-label treatment trials and small numbers. Partial gastrectomy and pyloroplasty should be used rarely, only in carefully selected patients. Attention should be given to the development of new effective therapies for symptomatic control. Am J Gastroenterol 2013; 108:18-37; doi:10.1038/ajg.2012.373; published online 13 November 2012
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available